DNA Methylation biomarkers to assess therapy and chemoprevention for non-small cell lung cancer.

The article presents a study which examines the role of DNA biomarkers to assess therapy and chemoprevention for non-small cell lung cancer. It is mentioned that methylation of multiple gene promoters in sputum is strongly associated with lung cancer risk and reinforces the use of gene methylation as a biomarker in the prevention trial. The study also revealed that sputum can be used as a surrogate for tumor tissue to predict the methylation status of advanced lung cancer in cases where biopsy is not feasible. Additionally, a bar graph which shows the frequency of methylation of multiple genes in sputum obtained from lung cancer survivors and smokers is presented.